Episode 15 - WHAT’S NEW DOC? End-of-the-Year Updates on Idiopathic Pulmonary Fibrosis

New analyses show rising prevalence of progressive pulmonary fibrosis, persistent diagnostic delays, and continued gaps in antifibrotic use. Fresh data from major trials, including nerandomilast, inhaled treprostinil, admilparant, deupirfenidone, and nalbuphine ER for chronic cough, point to meaningful advances on the horizon. At the same time, patient-centered research highlights the need for clearer communication, coordinated care, and earlier intervention to improve daily functioning and long-term outcomes. This CME activity brings all these findings together in one clear, concise program that helps clinicians keep pace with a rapidly changing field and deliver more effective, patient-focused care.Launch/Release Date: December 9, 2025 Activity Expiration Date: November 30, 2026This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.